Hybrigenics is a biotechnology and pharmaceutical company focusing its internal R&D programs on innovative target and therapeutics against cancer and commercializing its high throughput technology and bioinformatics platforms to identify, validate and inhibit protein interactions. Hybrigenics’ most advanced development program is based on inecalcitol, a vitamin D analogue, for prostate cancer in combination with current reference treatments, for improved efficacy and better tolerance. Hybrigenics’ research program explores the role of Ubiquitin-Specific Proteases (USPs) in the degradation of onco-proteins, and the use of proprietary USP inhibitors against various cancer types. Hybrigenics offers to researchers from all life sciences an access to its ISO 9001-certified Yeast-Two Hybrid (Y2H) high throughput screening platform, to its sophisticated bioinformatics set of tools and extensive database, and to its chemical library and high throughput small molecule screening platform, as fee-for-service activities. Hybrigenics is organized in two operational units: Hybrigenics Pharma for the internal R&D programs and Hybrigenics Services for the commercial business, coordinated with economies of scale by a common corporate, financial and administrative management.

Speaker Profile

Rémi Delansorne, Chief Executive Officer

Rémi Delansorne is Chief Executive Officer and a Director of Hybrigenics, a biotechnology company based in Paris. Rémi Delansorne was born in Paris in 1959. He graduated from the National Veterinary School of Alfort, France in 1981 and holds a Doctorate in Life Sciences from Pierre and Marie Curie University (Paris VI). In 1985, after a Post-Doctorate fellowship at the University of Texas Medical School in Houston, he joined the research laboratories of Théramex, a pharmaceutical company specialized in reproductive endocrinology and hormone-dependent oncology based in Monaco. In 1999, Rémi Delansorne became Head of the Pre-Clinical R&D Department before the takeover of Théramex by Merck Darmstadt (now Merck-Serono) in 2000. Within the same group, he held both positions of Preclinical R&D Administrator for the French sites and Global Head of Diabetes Research in 2002 and 2003. Rémi Delansorne joined Hybrigenics in 2004 as Vice-President for R&D and became Chief Executive Officer in 2005.